Elanco Animal Health (ELAN) Other Non-Current Liabilities (2017 - 2026)
Elanco Animal Health (ELAN) posted Other Non-Current Liabilities of $467.0 million for Q1 2026, up 53.62% sequentially from $304.0 million in Q4 2025, and down 4.11% YoY from $487.0 million in Q1 2025.
Elanco Animal Health (ELAN) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Elanco Animal Health has reported Other Non-Current Liabilities for 10 years, with the latest figure at $467.0 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 4.11% year-over-year to $467.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $467.0 million (down 4.11% YoY) and the FY2025 annual result came in at $304.0 million, up 0.66% from the prior year.
- Other Non-Current Liabilities advanced to $467.0 million in Q1 2026 per ELAN's latest filing, from $304.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $638.0 million in Q2 2025 and troughed at $225.0 million in Q3 2022.
- A 5-year average of $398.1 million and a median of $411.0 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 93.47% in 2024, down 26.52% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $229.0 million in 2022, then surged by 79.48% to $411.0 million in 2023, then declined by 26.52% to $302.0 million in 2024, then rose by 0.66% to $304.0 million in 2025, then soared by 53.62% to $467.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $467.0 million, $304.0 million, and $607.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 551.00 Mn |
| Mar 31, 2026 | 467.00 Mn |
| Dec 31, 2025 | 304.00 Mn |
| Sep 30, 2025 | 607.00 Mn |
| Jun 30, 2025 | 638.00 Mn |
| Mar 31, 2025 | 487.00 Mn |
| Dec 31, 2024 | 302.00 Mn |
| Sep 30, 2024 | 587.00 Mn |
| Jun 30, 2024 | 465.00 Mn |
| Mar 31, 2024 | 474.00 Mn |
| Dec 31, 2023 | 411.00 Mn |
| Sep 30, 2023 | 432.00 Mn |
| Jun 30, 2023 | 411.00 Mn |
| Mar 31, 2023 | 245.00 Mn |
| Dec 31, 2022 | 229.00 Mn |
| Sep 30, 2022 | 225.00 Mn |
| Jun 30, 2022 | 242.00 Mn |
| Mar 31, 2022 | 242.00 Mn |
| Dec 31, 2021 | 262.00 Mn |
| Sep 30, 2021 | 220.00 Mn |